Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials.

In the MRD trial, the time to reach peak plasma cGMP concentration was approximately 1 h after BI 685509 administration; although there was a slight trend toward higher mean cGMP levels at higher BI 685509 doses, there was no definitive evidence of a dose-dependent effect.

also in 3,746 other papers